132 related articles for article (PubMed ID: 23548469)
1. Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients.
Kilpatrick RD; Newsome BB; Zaun D; Liu J; Solid CA; Nieman K; St Peter WL
Am J Nephrol; 2013; 37(4):389-98. PubMed ID: 23548469
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
4. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
6. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
11. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
Reams BD; Dluzniewski PJ; Do TP; Yue SV; Bradbury BD; Kshirsagar AV; Brookhart MA
BMC Nephrol; 2015 Oct; 16():175. PubMed ID: 26510587
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
19. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]